David R. Greeley, MD – FDA 483, Mar 25, 2022
An FDA inspection of David R. Greeley, MD in Spokane, WA, revealed significant deficiencies in the conduct of clinical investigations for Alzheimer's Disease drug studies. The firm failed to adhere to investigational plans, including dosing subjects with unresolved adverse events and not reporting adverse events from MRI findings in a timely or accurate manner. Additionally, the firm did not maintain adequate and accurate case histories, specifically regarding the documentation of sedation medications for subjects undergoing MRIs.
ID · 0d6396fa-bfff-4636-8c8f-1c5cf6ece8a2
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.